Palvella Therapeutics (PVLA) Net Margin (2016 - 2024)
Historic Net Margin for Palvella Therapeutics (PVLA) over the last 11 years, with Q4 2024 value amounting to 1861.33%.
- Palvella Therapeutics' Net Margin rose 7958100.0% to 1861.33% in Q4 2024 from the same period last year, while for Dec 2024 it was 13620.31%, marking a year-over-year increase of 136436600.0%. This contributed to the annual value of 4054.42% for FY2024, which is 40125700.0% up from last year.
- Latest data reveals that Palvella Therapeutics reported Net Margin of 1861.33% as of Q4 2024, which was up 7958100.0% from 5150.94% recorded in Q1 2024.
- In the past 5 years, Palvella Therapeutics' Net Margin registered a high of 1861.33% during Q4 2024, and its lowest value of 5150.94% during Q1 2024.
- Its 5-year average for Net Margin is 341.6%, with a median of 160.69% in 2021.
- As far as peak fluctuations go, Palvella Therapeutics' Net Margin soared by 12565500bps in 2023, and later tumbled by -43970100bps in 2024.
- Over the past 5 years, Palvella Therapeutics' Net Margin (Quarter) stood at 660.79% in 2020, then skyrocketed by 80bps to 130.34% in 2021, then tumbled by -47bps to 191.04% in 2022, then surged by 658bps to 1065.51% in 2023, then soared by 75bps to 1861.33% in 2024.
- Its Net Margin was 1861.33% in Q4 2024, compared to 5150.94% in Q1 2024 and 1065.51% in Q4 2023.